To the full analysis
Clorox stock: growth
CLXClorox reported $6.72B in revenue for fiscal 2026, down 5.4% on the prior year, down 1.8% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
1.7%
per year from 2007 to 2026, per share 2.9%
Earnings (Annual rate)
0.8%
per year from 2007 to 2026, per share 2%
Free cash flow (Annual rate)
−1.7%
per year from 2007 to 2026, per share −0.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | −1.8% | 1.6% | 1.7% |
| Revenue per share | −1.1% | 2.2% | 2.9% |
| Earnings | −3.7% | −1.0% | 0.8% |
| Earnings per share | −3.1% | −0.4% | 2.0% |
| Free cash flow | −15.6% | −3.9% | −1.7% |
| Free cash flow per share | −15.1% | −3.4% | −0.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $4.85B | $501M | $562M |
| 2008 | $5.27B | $461M | $560M |
| 2009 | $5.45B | $537M | $541M |
| 2010 | $5.23B | $603M | $616M |
| 2011 | $5.23B | $557M | $470M |
| 2012 | $5.47B | $541M | $420M |
| 2013 | $5.53B | $572M | $581M |
| 2014 | $5.51B | $558M | $629M |
| 2015 | $5.66B | $580M | $749M |
| 2016 | $5.76B | $648M | $606M |
| 2017 | $5.97B | $701M | $637M |
| 2018 | $6.12B | $823M | $780M |
| 2019 | $6.21B | $820M | $786M |
| 2020 | $6.72B | $939M | $1.29B |
| 2021 | $7.34B | $710M | $945M |
| 2022 | $7.11B | $462M | $535M |
| 2023 | $7.39B | $149M | $930M |
| 2024 | $7.09B | $280M | $483M |
| 2025 | $7.1B | $810M | $761M |
| 2026 | $6.72B | $587M | $405M |
Revenue by segment
How The Clorox Company makes its money and how that has shifted. Names are as the company reports them.
- Health and Wellness40%
- Household27%
- Lifestyle17%
- International17%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|---|---|
| Health and Wellness | $2.75B | $2.98B | $2.69B | $2.53B | $2.49B | $2.7B | $2.7B | 40.1% |
| Household | $1.8B | $1.98B | $1.98B | $2.1B | $1.95B | $2B | $1.79B | 26.6% |
| Lifestyle | $1.15B | $1.22B | $1.25B | $1.34B | $1.28B | $1.3B | $1.12B | 16.7% |
| International | $1.02B | $1.16B | $1.18B | $1.18B | $1.16B | $1.07B | $1.11B | 16.6% |
| Other | $0 | $0 | $0 | $240M | $221M | $0 | $0 | 0% |
| Total revenue | $6.72B | $7.34B | $7.11B | $7.39B | $7.09B | $7.1B | $6.72B | 100% |
Revenue by region
Where The Clorox Company generates its revenue.
- United States84%
- Foreign16%
Figures as a table
| 2025 | 2026 | Share 2026 | |
|---|---|---|---|
| United States | $6.08B | $5.63B | 83.8% |
| Foreign | $1.02B | $1.09B | 16.2% |
| Total revenue | $7.1B | $6.72B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Apr 2021)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.